Zafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
March 11, 2019 4:05 PM EDTRecently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061
Updates on progress preparing for FDA Type A meeting for ZGN-1061
Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies
Expanded executive team with highly experienced drug development leader, Dr. Priya Singhal, as Head of Research and Development
Company to host conference call today at 5:00 p.m. ET
BOSTON, March 11, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:... More
